

Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Klm Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowit Peter A. Jackman Brian J. Del Buono Mark Fox Evens Vincent L. Capuano Glizabeth J. Haanes Michael D. Specht kevin W. McCabe Glenn J. Perry Edward W. Yee Grant E. Reed Virgil Lee Beaston Theodore A. Wood Joseph S. Ostroff Jason D. Eisenberg Iracy L. Muller Jon E. Wright

Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou W. Blake Coblentz James J. Pohl John T. Haran Mark W. Rygiel Michael R. Malek\* Carla Ji-Eun Kim Doyle A. Siever\* Ulrike Winkler Jenks Paul A. Calvo Robert A. Schwartzman C. Matthew Rozier\* Shameek Ghose Randall K. Baldwin Daniel J. Nevrivy

Registered Patent Agents •
Karen R. Markowicz
Matthew J. Dowd
Mita Mukherjee
Scott M. Woodhouse
Peter A. Socarras

Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie Christopher P. Wrist

\*Admitted only in Maryland \*Admitted only in Virginia •Practice Limited to Federal Agencies

October 10, 2007

WRITER'S DIRECT NUMBER: (202) 772-8822 INTERNET ADDRESS: SCARROLL@SKGF.COM

Art Unit 1654

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application No. 10/553,669; § 371 Date: August 9, 2006

For: Nogo Receptor-1 Polypeptides for the Treatment of Conditions

Involving Amyloid Plaques (as amended)

Inventors: STRITTMATTER et al. Our Ref: 2159.0470001/EJH/SAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply Under 37 C.F.R. § 1.111, with Exhibit A.

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Shannon A. Carroll, Ph.D. Attorney for Applicants

Registration No. 58,240

SAC/rjv Enclosures

730870 1.DOC

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 4039

STRITTMATTER et al.

Art Unit: 1654

Appl. No.: 10/553,669

Examiner: Ha, Julie

§ 371 Date: August 9, 2006

For: Nogo Receptor-1 Polypeptides for the Treatment of Conditions

**Involving Amyloid Plaques (As** 

Atty. Docket: 2159.0470001/EJH/SAC

Amended)

## Amendment and Reply Under 37 C.F.R. § 1.111

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated July 11, 2007, Applicants submit the following Amendment and Remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks and Arguments begin on page 5 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.